

ASX Release

EMVision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION 1st GENERATION DEVICE PROGRESSING WELL

Highlights:

- *1st Gen device assembly on track for completion next month*
- *Development of consumable portfolio advancing positively*

EMvision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to provide an update on the build of its 1st Gen device.

The assembly of the 1st Gen device is on target, with the first device build to be completed next month. The 1st Gen device is the Company’s first model intended for commercialisation and is targeted for use in ICUs, stroke and neurology wards, angiogram suites and emergency departments. This device intends to offer a bedside decision support and monitoring capability for stroke patients.

The device, which is comparable in size to a cart-based ultrasound unit, can be wheeled directly to a patient’s bedside, for point of care neuroimaging, whether that patient is in a stroke or neurology ward, an intensive care unit, angiogram suite or emergency department. CAD images of the device are provided below.



The above CAD images show the 1st gen device, including headset, positioning arm and cart.

In addition to the development of the device, EMVision's product development team has advanced a series of consumable components and accessories that support the device's mode of operation.

The consumable components, pictured below, include a coupling medium and disposable caps. The coupling medium flows into a contained membrane in the headset and performs a similar function for electromagnetic ("EM") imaging as ultrasound gel where during an ultrasound examination the gel facilitates the transmission of ultrasound waves from the probe to the tissues under examination. The EM coupling medium container is pictured below, with the proprietary EM coupling medium anticipated to be replaced after a set volume of scans. The single use disposable cap is designed to provide infection control, which is top of mind as a result of COVID-19, as well as assisting the operator in positioning of the headset on the patients' head.



The above CAD images show the EM coupling system (L) and disposable cap (R)

In addition, a series of accessories have been developed in consultation with our clinical collaborators to support patient comfort (including neck support). The 1st Gen units will be the subject of various tests including functional, reliability, integration (software and hardware) and preliminary safety, performance and compliance tests in preparation for expanded clinical studies. Product suitability for manufacturability, assembly, shipment (environmental impact), use, service and repair will also be assessed.

The Company advises that it has not been materially impacted by recent COVID-19 restrictions in NSW and the Company is currently able to progress its key activities in line with NSW Government Health guidelines.

EMVision CEO, Dr Ron Weinberger, commented "Despite the COVID-19 restrictions in NSW we have been able to keep progressing well to our targets. Substantial effort has gone into design for manufacture and reducing our bill of materials in line with our commercial objectives. Particularly exciting are the developments in our consumable portfolio. Consumables have potential to contribute an attractive annuity income stream for the Company."

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 800
andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$1.6 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Tropon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.